Open Access<p>Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil</p>
Author(s) -
Marion Ortner,
Marion Stange,
Heike Schneider,
Charlotte Schröder,
Katharina Büerger,
Cláudia Müller,
Felix MüllerSarnowski,
Janine DiehlSchmid,
Hans Förstl,
Timo Grimmer,
Werner Steimer
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s247259
Subject(s) - donepezil , rivastigmine , cyp2d6 , pharmacology , drug , drug metabolism , medicine , genotype , pharmacokinetics , metabolism , chemistry , cytochrome p450 , dementia , biochemistry , disease , gene
The efficacy of acetylcholinesterase inhibitors (AChE-I) might depend on blood concentration. While rivastigmine metabolism is independent of the cytochrome P450 system, its isoenzymes, especially CYP2D6, metabolize donepezil. CYP2D6 polymorphisms can cause altered enzyme activity resulting in lower or higher than expected drug concentrations of donepezil.